 |
BioLok International Inc. (OTC) manufactures and distributes products that merge cell biology and technology to develop and market products for the dental implant and tissue regeneration markets |
|
Healthpoint Capital (HPC) is a private equity firm exclusively focused on the orthopedic and dental device businesses |
|
The Board of Directors of BioLok retained TM Capital to evaluate HPC’s proposed tender offer of $2.15 per share in cash, or $35 million, to acquire 100% of the outstanding shares of the company |
|
TM Capital analyzed the transaction and rendered a fairness opinion to the BioLok’s Board of Directors which was included in the company’s shareholder documents and public filings |
MedTech Completes Recapitalization
Dinex Acquired by Carlisle Companies
Immucor Acquires BioArray Solutions
Immucor Forms Joint Venture with Kainos
Immucor Acquires Gamma Biologicals
SteriGenics Acquired by IBA
SteriGenics Acquires Nicolet from Thermo
Portland Professional Acquired by NMHC
Jensen Completes Recapitalization
Heico Sells Meditek to U.S. Diagnostic Labs
Medical Diagnostics Acquired by ANMR
Medcom Acquired by Quintiles
Armstrong Pharma Acquired by Medeva
International Murex Completes Financing
Immucor Acquires Division of Biopool
Immucor Completes Debt Restructuring
Immucor Board of Directors Re-Elected
Immucor Goodwill Valuation Analysis
SteriGenics Acquires Irradiation Industries
SteriGenics Int'l Acquires RTI
BioLok Acquired by Healthpoint Capital
